HC Wainwright Reiterates Buy Rating for Actinium Pharmaceuticals (NYSEAMERICAN:ATNM)

Actinium Pharmaceuticals (NYSEAMERICAN:ATNM)‘s stock had its “buy” rating reaffirmed by investment analysts at HC Wainwright in a research report issued on Thursday, Benzinga reports. They currently have a $50.00 target price on the biotechnology company’s stock.

A number of other equities research analysts have also weighed in on ATNM. HSBC began coverage on Actinium Pharmaceuticals in a research report on Wednesday. They set a “buy” rating and a $11.60 target price for the company. StockNews.com raised Actinium Pharmaceuticals to a “sell” rating in a research report on Thursday. One investment analyst has rated the stock with a sell rating, one has given a hold rating and three have given a buy rating to the stock. Based on data from MarketBeat, Actinium Pharmaceuticals presently has a consensus rating of “Hold” and an average target price of $28.32.

Actinium Pharmaceuticals Price Performance

Shares of ATNM opened at $6.53 on Thursday. The company’s 50 day simple moving average is $9.53. The company has a market cap of $176.31 million, a P/E ratio of -3.61 and a beta of 0.38. Actinium Pharmaceuticals has a 12-month low of $5.87 and a 12-month high of $15.12.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the business. UBS Group AG boosted its position in shares of Actinium Pharmaceuticals by 76.2% during the fourth quarter. UBS Group AG now owns 3,235 shares of the biotechnology company’s stock worth $34,000 after buying an additional 1,399 shares during the period. Quent Capital LLC purchased a new position in shares of Actinium Pharmaceuticals during the second quarter worth $37,000. Royal Bank of Canada boosted its position in shares of Actinium Pharmaceuticals by 38.5% during the second quarter. Royal Bank of Canada now owns 6,734 shares of the biotechnology company’s stock worth $49,000 after buying an additional 1,871 shares during the period. California State Teachers Retirement System acquired a new position in Actinium Pharmaceuticals during the 2nd quarter worth $64,000. Finally, The Manufacturers Life Insurance Company acquired a new position in Actinium Pharmaceuticals during the 2nd quarter worth $83,000. 22.38% of the stock is currently owned by hedge funds and other institutional investors.

About Actinium Pharmaceuticals

Actinium Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops targeted radiotherapies to deliver cancer-killing radiation to treat patients with high unmet medical needs. Its lead product candidate, I-131 apamistamab (Iomab-B) that is in a pivotal Phase III clinical trial for elderly relapsed or refractory acute myeloid leukemia trial for bone marrow transplant conditioning; and a Phase I study with a CD19- targeted CAR T-cell therapy with memorial sloan kettering cancer center.